Physicians' Academy for Cardiovascular Education

Treatment with statin before PCI intervention reduces MACE in patients with ACS

3' education - Mar. 11, 2018 - ACC 2018, Orlando, FL, VS - Otavio Berwanger - São Paulo, Brasil

Results ODYSSEY OUTCOMES study can change clinical practice for treatment of high-risk ACS patients

3' education - Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Dr. Valentin Fuster, New York, NY, USA

Treatment of patients on oral anticoagulation who present with ACS

10' education - Sep. 15, 2017 - Dr. Jur ten Berg - Cardiologist, Nieuwegein, The Netherlands
##SCROLLER_ITEMS_FULL_TITLE##

Customising therapy approach in ACS based on underlying pathology seems promising

3' education - Oct. 21, 2016 - ESC - 2016 Rome - Ik-Kyung Jang, MD - Massachusetts General Hospital, Boston, MA, USA

No added value of monitoring platelet function after ACS

3' education - Oct. 6, 2016 - ESC - 2016 Rome - Stefan Gielen, MD - University of Leipzig, Germany
##SCROLLER_ITEMS_FULL_TITLE##

No indication for difference in efficacy between potent platelet inhibitors after PCI

3' education - Aug. 30, 2016 - ESC - 2016 Rome - Steen Dalby Kristensen, MD - Aarhus University, Denmark

Novel strategies targeting residual risk: The promise of PCSK9 inhibiting therapies

10' education - Aug. 28, 2016 - ESC 2016, Rome - Erik Stroes, MD – Academic Medical Center, Amsterdam, The Netherlands - PACE-CME symposium held at ESC 2016 in Rome

Evolving hypotheses on the mechanisms underlying ACS

3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Peter Libby, MD - Boston, MA, USA

Changing views on mechanisms of atherosclerosis

10' education - Feb. 12, 2016 - Boston, MA, USA - Prof. Peter Libby (Boston, MA, USA)

C-Reactive Protein, Inflammation and Atherosclerosis

Jan. 24, 2016
##SCROLLER_ITEMS_FULL_TITLE##

Inflammation as target for therapy in atherothrombosis

10' education - Aug. 31, 2015 - ESC London - Prof Paul M Ridker
##SCROLLER_ITEMS_FULL_TITLE##

Inflammation and Thrombosis

10' education - Sep. 29, 2015
##SCROLLER_ITEMS_FULL_TITLE##

The changing character of atherosclerotic disease

3' education - May 24, 2015 - ISA2015, Amsterdam - Prof. Peter Libby

Cardiovascular Inflammation and Immunity in Atherosclerosis:

10' education - June 7, 2015 - Amsterdam
##SCROLLER_ITEMS_FULL_TITLE##

HDL mimetics: New promise in ACS?

3' education - Sep. 15, 2014 - Barcelona 2014 - Prof Kausik Ray MD
##SCROLLER_ITEMS_FULL_TITLE##

New registries on ACS/PCI: how does the real world look like

10' education - Sep. 2, 2014 - Barcelona, ESC - Peter Sinnaeve, MD UZ Leuven
##SCROLLER_ITEMS_FULL_TITLE##

Latest guidelines on ACS/PCI: what are the key changes?

10' education - Sep. 2, 2014 - Barcelona, ESC - Prof. Petr Widimsky, Prague, Czech Republic
##SCROLLER_ITEMS_FULL_TITLE##

ACS/PCI :Patient cases based on real world data

10' education - Sep. 2, 2014 - Barcelona, ESC - Peter Sinnaeve, MD UZ Leuven
##SCROLLER_ITEMS_FULL_TITLE##

ACS/PCI: Patient cases based on latest guidelines

10' education - Sep. 1, 2014 - Barcelona, ESC - Professor Petr Widimský

Statin-loaded HDL nanoparticles

10' education - Jan. 23, 2014 - Raphaël Duivenvoorden - Raphaël Duivenvoorden

Treatment with statin before PCI intervention reduces MACE in patients with ACS

3' education - Mar. 11, 2018 - ACC 2018, Orlando, FL, VS - Otavio Berwanger - São Paulo, Brasil
Results of the SECURE-PCI trial showed a 28% decrease of MACE in patients treated with avorstatin compared to placebo before PCI intervention after ACS.

ACC 2018 Results of the SECURE-PCI trial showed a 28% decrease of MACE in patients treated with avorstatin compared to placebo before PCI intervention after ACS.

Genetic information to guide antiplatelet selection after ACS can improve outcomes

Presented at ACC.18 by Diego Ardissino (Azienda Ospedaliero - Universitaria di Parma, Italy)

News - Mar. 11, 2018

ACC 2018 When clinical characteristics were combined with genetic information to inform the choice of P2Y12 inhibitor after ACS, patients experienced 42% fewer MI, stroke, CV death or major bleeding.

Results ODYSSEY OUTCOMES study can change clinical practice for treatment of high-risk ACS patients

3' education - Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Dr. Valentin Fuster, New York, NY, USA
Dr. Valentin Fuster explains why he thinks that the ODYSSEY OUTCOMES results with the PCSK9 inhibitor alirocumab can change clinical practice. In the results he also sees the message that LDL levels now considered normal, may actually be too high.

ACC 2018 Dr. Valentin Fuster explains why he thinks that the results with the PCSK9 inhibitor alirocumab can change clinical practice. In the results he also sees the message that LDL levels now considered normal, may actually be too high.

Another PCSK9 inhibitor safely reduces MACE in long term outcomes trial in high-risk patients

Presented at ACC.18 by Ph. Gabriel Steg (Paris, France)

News - Mar. 9, 2018
Treatment with alirocumab on top of high-intensity statins lowered MACE by 15% in patients with recent ACS in the ODYSSEY OUTCOMES trial and was associated with a lower rate of all-cause death.

ACC 2018 Treatment with alirocumab on top of high-intensity statins lowered MACE by 15% in patients with recent ACS in the ODYSSEY OUTCOMES trial and was associated with a lower rate of all-cause death.

Suboptimal medical therapy for ACS patients is associated with increased mortality

Literature - Feb. 15, 2018 - Hoedemaker NPG et al. - Eur Heart J - CV Pharmacotherapy 2018

In a single-center observational study, less than 50% of acute coronary syndrome patients were on recommended therapies at discharge, which was associated with an increase in 1-year mortality.

Post-ACS patients do not benefit from addition of a NOAC to DAPT

Literature - Jan. 18, 2018 - Khan SU et al. - Am J Cardiol 2018
Meta-analysis shows that in patients with recent ACS, addition of a NOAC to dual antiplatelet therapy resulted in a modest reduction of major adverse CV events but led to higher bleeding risk.

Meta-analysis shows that in patients with recent ACS, addition of a NOAC to dual antiplatelet therapy resulted in a modest reduction of major adverse CV events but led to higher bleeding risk.

2017 ESC STEMI guidelines redefine important time points, with consequences for management choices

News - Jan. 16, 2018

Two documents summarize the main messages of the ESC 2017 STEMI management guidelines, namely changes with respect to the 2012 version and ‘ten commandments’ to follow.

DAPT improves patency of saphenous vein graft at 1 year post-CABG

Presented at ACC.17 Scientific Sessions in Anaheim, CA, USA by Qiang Zhao (Ruijin Hospital, Shanghai)

News - Nov. 13, 2017
The small DACAB study demonstrated that DAPT with ticagrelor plus aspirin more often showed patency of SVG and was associated with numerically lower MACE at 1 year as compared with aspirin alone.

AHA 2017 The small DACAB study demonstrated that DAPT with ticagrelor plus aspirin more often showed patency of SVG and was associated with numerically lower MACE at 1 year as compared with aspirin alone.

Treatment of patients on oral anticoagulation who present with ACS

10' education - Sep. 15, 2017 - Dr. Jur ten Berg - Cardiologist, Nieuwegein, The Netherlands
Using a case description and study data, dr. Jur ten Berg explains how management of these ACS patients differs from patients who are not anticoagulated with NOACs.

Using a case description and study data, dr. Jur ten Berg explains how management of these ACS patients differs from patients who are not anticoagulated with NOACs.

NOAC-based dual therapy is safer than triple therapy for stent placement in AF patients

ESC 2017 - Barcelona

News - Aug. 31, 2017

ESC 2017 Fewer major bleedings with dual therapy of dabigatran and platelet inhibitor than with triple therapy with warfarin, platelet inhibitor and aspirin, in AF patients receiving a stent in RE-DUAL PCI..

Longer-term treatment with low-dose P2Y12 inhibitor lowers mortality in high-risk ACS patients

ESC 2017 - Barcelona

News - Sep. 3, 2017

ESC 2017 PEGASUS substudy shows that continued treatment with ticagrelor within 2 years after MI or 1 year after stopping ADP receptor inhibition, reduces CV death in patients at high atherothrombotic risk.

GRAND DEBATE: Inflammation and cardiovascular disease

ESC 2017 - Barcelona

ESC 2017 Grand Debate
ESC 2017 Grand Debate

ESC 2017 One of the Grand Debates of course focused on different interpretations of the CANTOS trial data. Paul Ridker and Alberico Catapano debated how central inflammation is to CVD.